Neo-adjuvant chemotherapy (NACT) is an integral part of multi-modality approach in the management of locally advanced breast cancer (LABC). It is required both for the local control (to ensure microscopically free margins during surgery) and distant or systemic control [1-6]. Development of resistance to chemotherapeutic agents is a major and evolving problem. Various markers like P-Glycoprotein, tumor suppressor gene p53, apoptotic markers( Bcl-2, Bax) have been studied to predict the response to NACT[1].

Key words: Hemoglobin, breast cancer, neoadjuvant, Chemotherapy.